67. 多発性嚢胞腎 Polycystic kidney disease Clinical trials / Disease details
臨床試験数 : 216 / 薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151
Showing 1 to 10 of 216 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04939935 (ClinicalTrials.gov) | April 2022 | 16/6/2021 | Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease( ... | Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): A Randomised Placebo-Controlled Trial Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease( ... | Autosomal Dominant Polycystic Kidney Disease | Drug: Metformin XR;Other: Control | The University of Queensland | NULL | Not yet recruiting | 18 Years | 70 Years | All | 1164 | Phase 3 | Australia |
| 2 | EUCTR2021-003062-12-SK (EUCTR) | 11/03/2022 | 16/11/2021 | A clinical trial to look at how safe and how effective Lixivaptan is in patients with kidney disease compared to a placebo treatment. A clinical trial to look at how safe and how effective Lixivaptan is in patients with kidney disease ... | A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-Label Phase: The ACTION Study. - ACTION A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Pol ... | Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 100 ... | Product Name: Lixivaptan Product Code: 0C23 INN or Proposed INN: Lixivaptan Other descriptive name: Lixivaptan Product Name: Lixivaptan Product Code: 0C23 INN or Proposed INN: Lixivaptan Other descriptive name: Lix ... | Palladio Biosciences Inc. | ,NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 1350 | Phase 3 | Portugal;Belarus;Serbia;United States;Slovakia;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;France;Peru;Australia;Denmark;Turkey;United Kingdom;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Georgia;Bulgaria;Germany;New Zealand Portugal;Belarus;Serbia;United States;Slovakia;Spain;Ukraine;Israel;Chile;Russian Federation;Colombi ... | ||
| 3 | NCT05190744 (ClinicalTrials.gov) | March 1, 2022 | 29/12/2021 | PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKDTreated With Tolvaptan, and Severely Pol ... | A Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine Output and Increasing the Urine Osmolality in Patients With Hereditary Nephrogenic Diabetes Insipidus, Patients With Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan, And Severely Polyuric Patients With Previous Lithium Administration (Serendipity-PB1) A Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine O ... | Autosomal Dominant Polycystic Kidney Disease;Nephrogenic Diabetes Insipidus;Acquired Nephrogenic Diabetes Insipidus;Congenital Nephrogenic Diabetes Insipidus Autosomal Dominant Polycystic Kidney Disease;Nephrogenic Diabetes Insipidus;Acquired Nephrogenic Dia ... | Drug: PB | Mayo Clinic | Hopital du Sacre-Coeur de Montreal | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 4 | NCT05208866 (ClinicalTrials.gov) | February 10, 2022 | 7/1/2022 | Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303 Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKDWho Completed Study PA-ADPK ... | PA-ADPKD-304: A Phase 3, Open-label, Roll-over Study to Assess Long-term Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Who Completed Study PA-ADPKD-303: The ALERT Study PA-ADPKD-304: A Phase 3, Open-label, Roll-over Study to Assess Long-term Safety of Lixivaptan in Par ... | Polycystic Kidney Disease, Adult | Drug: Lixivaptan | Palladio Biosciences | NULL | Enrolling by invitation | 18 Years | N/A | All | 12 | Phase 3 | United States |
| 5 | EUCTR2021-003062-12-BG (EUCTR) | 09/02/2022 | 06/12/2021 | A clinical trial to look at how safe and how effective Lixivaptan is in patients with kidney disease compared to a placebo treatment. A clinical trial to look at how safe and how effective Lixivaptan is in patients with kidney disease ... | A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-Label Phase: The ACTION Study. - ACTION A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Pol ... | Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 100 ... | Product Name: Lixivaptan Product Code: 0C23 INN or Proposed INN: Lixivaptan Other descriptive name: Lixivaptan Product Name: Lixivaptan Product Code: 0C23 INN or Proposed INN: Lixivaptan Other descriptive name: Lix ... | Palladio Biosciences Inc. | ,NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 1200 | Phase 3 | United States;Serbia;Slovakia;Spain;Ukraine;Turkey;Israel;Chile;Colombia;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Australia;Peru;Bulgaria;Georgia United States;Serbia;Slovakia;Spain;Ukraine;Turkey;Israel;Chile;Colombia;United Kingdom;Italy;France ... | ||
| 6 | EUCTR2021-003062-12-ES (EUCTR) | 21/01/2022 | 20/10/2021 | A clinical trial to look at how safe and how effective Lixivaptan is in patients with kidney disease compared to a placebo treatment. A clinical trial to look at how safe and how effective Lixivaptan is in patients with kidney disease ... | A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-Label Phase: The ACTION Study. - ACTION A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Pol ... | Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 100 ... | Product Name: Lixivaptan Product Code: 0C23 INN or Proposed INN: Lixivaptan Other descriptive name: Lixivaptan Product Name: Lixivaptan Product Code: 0C23 INN or Proposed INN: Lixivaptan Other descriptive name: Lix ... | Palladio Biosciences Inc. | ,NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 1200 | Phase 3 | United States;Serbia;Slovakia;Spain;Ukraine;Turkey;Chile;Israel;Colombia;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Australia;Peru;Bulgaria;Georgia United States;Serbia;Slovakia;Spain;Ukraine;Turkey;Chile;Israel;Colombia;United Kingdom;Italy;France ... | ||
| 7 | EUCTR2021-003062-12-IT (EUCTR) | 20/01/2022 | 18/10/2021 | A clinical trial to look at how safe and how effective Lixivaptan in patients with kidney disease compared to a placebo treatment. A clinical trial to look at how safe and how effective Lixivaptan in patients with kidney disease co ... | A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-Label Phase: The ACTION Study. - ACTION A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Pol ... | Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 100 ... | Product Name: Lixivaptan Product Code: [0C23] INN or Proposed INN: Lixivaptan | Palladio Biosciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 1200 | Phase 3 | United States;Serbia;Slovakia;Spain;Ukraine;Turkey;Chile;Israel;Colombia;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Australia;Peru;Bulgaria;Georgia United States;Serbia;Slovakia;Spain;Ukraine;Turkey;Chile;Israel;Colombia;United Kingdom;Italy;France ... | ||
| 8 | EUCTR2021-002551-11-DK (EUCTR) | 18/01/2022 | 27/05/2021 | Chronic kidney disease – imaging the metabolic derangements with ultra-sensitive MRI | Chronic kidney disease – imaging the metabolic derangements with ultra-sensitive MRI | Chronic kidney disease and polycystic kidney disease MedDRA version: 23.1;Level: PT;Classification code 10064848;Term: Chronic kidney disease;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05] Chronic kidney disease and polycystic kidney disease MedDRA version: 23.1;Level: PT;Classification c ... | Product Name: Hyperpolarized [1-13C]pyruvate INN or Proposed INN: SODIUM PYRUVATE Other descriptive name: SODIUM PYRUVATE Product Name: Hyperpolarized [1-13C]pyruvate INN or Proposed INN: SODIUM PYRUVATE Other descriptive na ... | Aarhus University | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Denmark | ||
| 9 | EUCTR2021-003062-12-HU (EUCTR) | 03/01/2022 | 05/11/2021 | A clinical trial to look at how safe and how effective Lixivaptan is in patients with kidney disease compared to a placebo treatment. A clinical trial to look at how safe and how effective Lixivaptan is in patients with kidney disease ... | A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-Label Phase: The ACTION Study. - ACTION A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Pol ... | Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 100 ... | Product Name: Lixivaptan Product Code: 0C23 INN or Proposed INN: Lixivaptan Other descriptive name: Lixivaptan Product Name: Lixivaptan Product Code: 0C23 INN or Proposed INN: Lixivaptan Other descriptive name: Lix ... | Palladio Biosciences Inc. | ,NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 1200 | Phase 3 | United States;Serbia;Slovakia;Spain;Ukraine;Turkey;Chile;Israel;Colombia;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Australia;Peru;Bulgaria;Georgia United States;Serbia;Slovakia;Spain;Ukraine;Turkey;Chile;Israel;Colombia;United Kingdom;Italy;France ... | ||
| 10 | EUCTR2020-000433-40-NL (EUCTR) | 30/12/2021 | 03/08/2021 | Treatment of stiffness in blood vessels in patients with familial cystic kidney disease | Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease - TRAMPOLINE Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease- TRAMP ... | Autosomal dominant polycystic kidney disease;Therapeutic area: Not possible to specify | Trade Name: Amiloride Product Name: Amiloride INN or Proposed INN: AMILORIDE Trade Name: Sodium Chloride INN or Proposed INN: Sodium chloride Other descriptive name: Sodium Chloride Trade Name: Amiloride Product Name: Amiloride INN or Proposed INN: AMILORIDE Trade Name: Sodium Chlorid ... | Erasmus University Medical Centre Rotterdam | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 54 | Phase 4 | Netherlands |